Formula Grant 2101NCSCID

This Project Grant award of $200,016, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a non-viral genome editing therapy for Artemis-deficient Severe Combined Immunodeficiency (ART-SCID). The principal investigator, Dr. Matthew Kan, a pediatric immunologist at the University of California, San Francisco (UCSF), aims to establish expertise in non-viral CRISPR/Cas9...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a multi-center observational study on silent cerebral infarction (SCI) in patients with immune thrombotic thrombocytopenic purpura (iTTP). The $438,682 award to The Johns Hopkins University, spanning 2024-2027, aims to elucidate the natural history of SCI, establish incidence and risk factors for new SCI and stroke during iTTP remission, and evaluate the impact of...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $563,588.00 to investigate the effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity, and COVID-19 clinical outcomes. The study aims to determine the specific immune defects linked to prolonged SARS-CoV-2 replication and acute disease, as well as the effect of different...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on investigating the impact of SARS-CoV-2 infection on the cerebrovascular system and its potential role as a risk factor for vascular contributions to cognitive impairment and dementia (VCID). The $1,120,805 award, granted to the University of Illinois, will examine three key...

This $192,888 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a research study to evaluate the generation, differentiation, breadth, and persistence of SARS-CoV-2-specific CD4+ and CD8+ T cell responses in patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). The goal is to provide in-depth knowledge on how antigen-specific T cell responses...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $463,125 research project investigating the role of cellular senescence in severe COVID-19 outcomes, particularly among individuals with obesity and non-alcoholic steatohepatitis (NASH). The project aims to study whether the removal of senescent cells can alleviate severe COVID-19 symptoms in mouse models and...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $770,502 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the molecular mechanisms underlying cerebral small vessel disease (CSVD) and its links to vascular contributions to cognitive impairment and dementia (VCID). The project aims to...

This $158,500 federal Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) will support research to evaluate the therapeutic potential of gene replacement for treating SCYL1 deficiency syndrome, a rare genetic disorder. The awardee, Trustees of Indiana University (doing business as Indiana University Indianapolis), will engineer two mouse models to study the effects of restoring SCYL1 gene expression. The research aims to provide evidence to advance...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $380,320.00 to support research focused on understanding human CD8 T cell responses to SARS-CoV-2 and how CD8 T cell dysfunction may contribute to the development of Long COVID. The key research objectives are to: 1) define the lineages and differentiation trajectories of functionally distinct CD8 T cell populations...

This $160,518 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of an independent investigator in the field of immune modulator cell therapy for critically ill children, particularly those post-hematopoietic stem cell transplant (HSCT). The key products and services to be delivered under this 5-year award include: Conducting an FDA- and IRB-approved Phase I clinical trial (NCT 05141058) to establish...